The Aethlon Hemopurifier
The Aethlon Hemopurifier® is a first-in-class technology designed for the rapid depletion of cancer-promoting exosomes and circulating viruses. The United States Food and Drug Administration (FDA) has designated the Hemopurifier® as a “Breakthrough Device” for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease; and life-threatening viruses that are not addressed with approved therapies.
We are currently conducting a safety, feasibility and dose-finding clinical trial of the Hemopurifier in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® (pembrolizumab) or Opdivo®(nivolumab) in Australia and India. The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial in each country is safety.
Our COVID-19 trial in India has two participating sites, the Medanta Medicity Hospital and Maulana Azad Medical College.
Information from previous clinical trials conducted in the United States is available on clinicaltrials.gov, hosted by the National Library of Medicine (NLM) at the National Institutes of Health (NIH) in Bethesda, Maryland
